TBPH icon

Theravance Biopharma

112 hedge funds and large institutions have $567M invested in Theravance Biopharma in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 35 increasing their positions, 45 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

more funds holding in top 10

Funds holding in top 10:

more ownership

Funds ownership:

more call options, than puts

Call options by funds: $ | Put options by funds: $

less capital invested

Capital invested by funds: $ → $

7% less funds holding

Funds holding: 120112 (-8)

22% less repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 45

40% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 15

Holders
112
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$1.28M
Puts
$1.24M
Net Calls
Net Calls Change

Top Buyers

1 +$25.7M
2 +$8.31M
3 +$7.47M
4
NM
Newtyn Management
New York
+$6.01M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.28M

Top Sellers

1 -$4.98M
2 -$3.65M
3 -$3.56M
4
Morgan Stanley
Morgan Stanley
New York
-$2.5M
5
BG
Baupost Group
Massachusetts
-$2.03M
Name Holding Trade Value Shares
Change
Change in
Stake
1
$122M
2
$65.9M
3
$59.3M
4
$56.5M
5
$45.5M
6
$28.8M
7
$24.4M
8
$20.3M
9
$18.5M
10
$13.5M
11
$12.5M
12
$10.5M
13
$9.31M
14
$7.79M
15
$6.12M
16
$5.39M
17
$5.28M
18
$4.94M
19
$4.56M
20
$3.56M
21
$2.37M
22
$2.29M
23
$2.18M
24
$1.95M
25
$1.88M